Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Products under Development by Stage of Development | 8 | 1 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Products under Development by Therapy Area | 9 | 1 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Products under Development by Indication | 10 | 1 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Products under Development by Companies | 13 | 2 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Products under Development by Universities/Institutes | 15 | 2 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 2 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Companies Involved in Therapeutics Development | 22 | 3 |
| Dicerna Pharmaceuticals, Inc. | 22 | 1 |
| Phylogica Limited | 23 | 1 |
| Sorrento Therapeutics, Inc. | 24 | 1 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Drug Profiles | 25 | 14 |
| DCRM-1711 Drug Profile | 25 | 4 |
| ES-4000 Drug Profile | 29 | 1 |
| JY-3094 Drug Profile | 30 | 1 |
| OMO-101 Drug Profile | 31 | 1 |
| Peptide to Inhibit c-Myc and mTOR for Chondrosarcoma and Oncology Drug Profile | 32 | 1 |
| Small Molecule to Target c-Myc for Multiple Myeloma Drug Profile | 33 | 1 |
| Small Molecules to Inhibit c-Myc for Oncology Drug Profile | 34 | 1 |
| Small Molecules to Inhibit c-Myc for Oncology Drug Profile | 35 | 1 |
| Small Molecules to Inhibit c-Myc for Solid Tumors and Hematological Malignancies Drug Profile | 36 | 1 |
| Small Molecules to Inhibit cMyc for Oncology Drug Profile | 37 | 1 |
| Synthetic Peptide to Inhibit c-Myc for Oncology Drug Profile | 38 | 1 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Dormant Projects | 39 | 2 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Discontinued Products | 41 | 1 |
| Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) Featured News &Press Releases | 42 | 7 |
| Dec 21, 2015: Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors | 42 | 1 |
| Dec 09, 2015: Combination therapy escalates potency of Phylogica peptides against MYC-driven cancer | 43 | 1 |
| Nov 16, 2015: Phylogica exceeds gold - standard for treatment of MYC - driven cancer | 44 | 1 |
| Jun 01, 2015: Dicerna Presents Preliminary Safety and Efficacy Data from DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors at the 2015 ASCO Annual Meeting | 45 | 1 |
| May 14, 2015: Dicerna Announces Expansion of Ongoing DCR-MYC Phase 1 Study to Evaluate Safety and Efficacy in Patients with Advanced Pancreatic Neuroendocrine Tumors (PNETs) | 46 | 1 |
| May 13, 2015: Dicerna to Present Interim Clinical Data from First DCR-MYC Phase 1 Study in Patients with Advanced Solid Tumors at the 2015 ASCO Annual Meeting | 46 | 1 |
| Feb 02, 2015: Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma | 47 | 1 |
| Apr 16, 2014: Dicerna Pharmaceuticals Initiates Phase 1 Study of DCR-MYC in Patients with Solid Tumors and Hematological Malignancies | 48 | 1 |
| Apr 02, 2013: Dicerna Pharma Announces First Patent Grant In Japan To Dicer Substrate siRNA Molecules | 48 | 1 |
| Appendix | 49 | 2 |
| Methodology | 49 | 1 |
| Coverage | 49 | 1 |
| Secondary Research | 49 | 1 |
| Primary Research | 49 | 1 |
| Expert Panel Validation | 49 | 1 |
| Contact Us | 49 | 1 |
| Disclaimer | 50 | 1 |
